Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Toxicity profile" patented technology

Toxicological profile ( toxicity profile ) An examination, summary, and interpretation of a hazardous substance to determine levels of exposure and associated health effects.

Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll- like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
Owner:DYNAVAX TECHNOLOGIES CORPORATION

"good"buffer-based cationic lipids

PendingAU2022259686B2Organic chemistryToxicity profile
The present invention provides, among other things, a novel class of cationic lipid compounds (e.g., cationic lipids having a structure according to Formula (I)) for in vivo delivery of therapeutic agents, such as nucleic acids. It is contemplated that these compounds are capable of highly effective in vivo delivery while maintaining a favorable toxicity profile.
Owner:TRANSLATE BIO INC

Compositions and Methods for the Prevention and Treatment of Hearing Loss

Method, kit, and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described as Dabrafenib is a therapeutic candidate for preventing cisplatin-induced hearing loss. It has a low effective dose of one tenth of the human equivalent dose (3 mg / kg administered twice day), a good toxicity profile, a therapeutic index of at least 25 in the multi-dose cisplatin regimen, protects both female and male mice, reduces hearing loss in two different strains of mice (FVB / NJ and CBA / CaJ), offers protection from weight loss that occurs during cisplatin chemotherapy, and persistence of hearing protection for at least four months after cisplatin treatments.
Owner:TING THERAPEUTICS INC

Compositions and methods relating to tumor activated t cell engagers

To provide a method for extending the half-life of a T cell engager and improving its toxicity profile.SOLUTION: The method comprises a step of binding a half-life extending molecule-linked inhibitory peptide mask to a T cell engager via a cleavable linker, in order to produce a modified T cell engager having reduced toxicity in healthy tissue as compared to an unmodified T cell engager. The cleavable linker is cleaved in the tumor microenvironment. The half-life extending molecule-linked inhibitory peptide mask is released from the modified T cell engager in order to produce a cleaved T cell engager. The modified T cell engager has a longer half-life than both the unmodified T cell engager and the cleaved T cell engager.SELECTED DRAWING: Figure 11
Owner:JANUX THERAPEUTICS INC

Compositions and methods for delivery of agents

This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
Owner:MODERNATX INC